Nama's AI scorecard currently rates Solventum Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SOLV's P/E ratio?

Solventum trades at a trailing price-to-earnings ratio of 12.8.

When does SOLV report earnings?

Solventum's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.78.

What is the SOLV price target?

The median analyst price target from 13 analysts is $100.00, with a range of $71.00 – $113.00.

Is SOLV Shariah compliant?

Nama's AAOIFI-style screen reads Solventum as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Solventum (SOLV)

Healthcare · Medical Instruments Supplies · NYSE

S&P 500

Solventum (SOLV) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $15.38B, a trailing price-to-earnings ratio of 12.8 and a free-cash-flow yield of -0.1%. Over the most recent reported fiscal year, revenue grew 0.9% and free cash flow per share fell 101.2%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +29.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.0%

How far the last close sits under the highest price of the past five years.

Market cap	$15.38B
Trailing P/E	12.8
Price / book	3.2
Price / sales	1.9
FCF yield	-0.1%
Dividend yield	—
Gross margin	54.7%
Operating margin	6.3%
Net margin	17.3%
Revenue growth (YoY)	+0.9%
Revenue growth (3-yr annual)	+0.8%
EPS growth (YoY)	-8.8%
FCF/share growth (YoY)	-101.2%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

SOLV earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.78). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$1.45	$1.34	+8.2%	—
Q2 2026	Aug 5, 2026	$2.55	$1.91	+33.5%	$2.21B
Q1 2026	May 5, 2026	$1.48	$1.35	+9.6%	$2.01B
Q4 2025	Feb 26, 2026	$1.57	$1.50	+4.7%	$2.00B

SOLV analyst price target

Median target $100.00 from 13 analysts, ranging $71.00 – $113.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
BAX	Baxter International	$13.34B	13.3
COO	Cooper Companies	$11.86B	13.5

Explore live SOLV data on Nama Insights →

Recent Congressional trades

Solventum trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas H Tuberville	Senate	Sell	$1,001 - $15,000	Aug 5, 2026
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
James French Hill	House	Sell	$15,001 - $50,000	Jan 23, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Feb 12, 2025

SOLV FAQ

Is SOLV a buy?: Nama's AI scorecard currently rates Solventum Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SOLV's P/E ratio?: Solventum trades at a trailing price-to-earnings ratio of 12.8.
When does SOLV report earnings?: Solventum's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.78.
What is the SOLV price target?: The median analyst price target from 13 analysts is $100.00, with a range of $71.00 – $113.00.
Is SOLV Shariah compliant?: Nama's AAOIFI-style screen reads Solventum as Not Shariah Compliant. At least one of the three ratios or the industry test failed.